Tetra Bio-Pharma Issues Operational Update Regarding COVID-19
Tetra Bio-Pharma Inc (TSXV: TBP) has issued an update regarding the working conditions for its employees, as well as the status of current and forthcoming research initiatives in wake of the COVID-19 outbreak.
Tetra Bio-Pharma has provided an update on working conditions for its employees, stating that the company is adhering to all provincial and federal health recommendations. Employees have relocated to home offices where they have been conducting their workload, meanwhile all manufacturing staff have been provided with am updated safe work environment.
As of current, the company will continue on with all of its anticipated US and European regulatory activities including its Clinical Trial Applications, Experimental Studies Certificate, Drug Identification Number Applications, Investigational New Drug Applications, and Orphan Drug Designation- to name a few.
Presently, the company is planning to expand its clinical sites across the US and Canada, so that once the outbreak has been mitigated, Tetra will have enough patient subjects to enroll into its clinical studies. Tetra is anticipating to complete its ophthalmic clinical trial with patient dogs in accordance with its prescribed timeline between the third and fourth quarter of 2020. So far, half of the animal subjects have completed treatment, and the company has already began working on a second trial which will test a treatment for canine indolent corneal ulcers.
Regarding Tetra’s orphan drug HCC011, the company will be submitting a Clinical Trial Application and an Investigational New Drug Application in both the US and Canada for the initiation of a clinical trial. Tetra has a Pre- Investigational New Drug Application meeting request with the Federal Drug Administration- which the company says will commence as planned.
Tetra will also continue with the TALLC and Panag Pharma research and development exercises as planned, in addition to continuing on with its CB2 Therapeutics exercises. As of current, the company is not anticipating a significant disruption in drug supplies due to the COVID-19 outbreak.
However, the COVID-19 outbreak did slow down some of Tetra’s planned activities. The company’s Reborn and Serenity exercises have been delayed due to the potential lack of available clinics, subject enrollment, and physicians. As such, the company has instead shifted focus towards attaining clinical research data during the outbreak, so it can be prepared with adequate medical and scientific information regarding its HCC011 and CAUMZ drugs for future marketing applications.
Tetra Bio-Pharma is a Canadian biopharmaceutical company focused on developing cannabinoid treatments and prescription drugs through its approved clinical program.
Tetra Bio-Pharma Inc is currently trading at $0.21 on the TSX-Venture.
Information for this briefing was found via Sedar and Tetra Bio-Pharma Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
